Results 41 to 50 of about 7,708 (214)

A Novel Case of Spontaneous Coronary Artery Dissection During Cabergoline Therapy for Prolactinoma

JACC: Case Reports, 2020
We present a case of spontaneous coronary artery dissection associated with cabergoline treatment for prolactinoma. A 31-year-old woman with history of hypertension and prolactinoma, treated with cabergoline, presented with chest pain.
Shinichiro Ikeda, MD, Jeffrey Le, MD, Shivani Verma, MD, Benjamin A. Youdelman, MD   +3 more
doaj   +1 more source

A giant invasive macroprolactinoma with recurrent nasal bleeding as the first clinical presentation: case report and review of literature

BMC Endocrine Disorders, 2023
Background Giant prolactinoma (> 4 cm in dimension) is a rare disorder. Invasive macroprolactinoma has the potential to cause base of skull erosion and extend into the nasal cavity or even the sphenoid sinus.
Danting Li, Yan Wang, Huiwen Tan, Peiqiong Luo, Yerong Yu   +4 more
doaj   +1 more source

Parkinson's disease under dopamine replacement therapy as a human framework for studying addiction‐relevant mechanisms

Psychiatry and Clinical Neurosciences, EarlyView.
Addiction is a chronic relapsing condition characterized by compulsive reward seeking and impaired behavioral control, associated with major individual and societal burden. Mechanistic investigation in humans remains constrained by ethical limitations, uncontrolled exposure histories, and ecological confounds.
Vanessa Fleury, Elvira Pirondini, Damien Benis, Tiffany Corbet, Gabriel Thorens, Christian Lüscher, Paul Krack   +6 more
wiley   +1 more source

Prolactinoma in a Dog [PDF]

Veterinary Pathology, 2017
A 12-year-old male Yorkshire Terrier was presented because of decreased appetite. Physical examination revealed mammary gland swelling and galactorrhea. Contrast-enhanced computed tomographic scanning of the skull indicated an enlarged pituitary gland, compatible with a pituitary tumor. The serum prolactin concentration was markedly elevated.
Cosio, Cristina, Sartori, Elena, Garatti, Marcello, Luccardini, Lorenzo, Grinwis, G. C. M., Kooistra, Hans S., Fracassi, Federico   +6 more
openaire   +5 more sources

Hypogonadotropic Hypogonadism Before and After Transsphenoidal Surgery for Non‐Functioning Pituitary Adenoma

Clinical Endocrinology, Volume 105, Issue 4, Page 442-451, October 2026.
ABSTRACT Objective The effect of transsphenoidal surgery (TSS) on the hypothalamic‐pituitary‐gonadal (HPG) axis in patients with non‐functioning pituitary adenomas (NFPA) is underexplored, especially in women. Our aim was to investigate the HPG axis function before and after TSS, its association with quality of life (QoL), and to identify factors that ...
Victor Hantelius, Gudmundur Johannsson, Sofie Jakobsson, Erik Thurin, Tobias Hallen, Thomas Skoglund, Oskar Ragnarsson   +6 more
wiley   +1 more source

A rare cranial disease: Prolactinoma-associated moyamoya syndrome [PDF]

Moyamoya disease is a rare chronic progressive cerebrovascular disease. The etiology of moyamoya disease has not been established yet. If an underlying cause is detected, moyamoya disease is called moyamoya syndrome.
Meryem Can, Erkingül Shugaiv, Ayberk Bayramgil, İrem İşlek   +3 more
core   +1 more source

Status epilepticus induced by treatment with dopamine agonist therapy for giant prolactinoma: a case report

Journal of Medical Case Reports, 2019
Background Dopamine agonists are the standard first-line medical therapy for prolactinoma. We report a rare case of giant prolactinoma with a first epileptic seizure due to rapid reduction of the tumor as a complication of dopamine agonist therapy.
Motofumi Koguchi, Yukiko Nakahara, Ryo Ebashi, Atsushi Ogata, Shoko Shimokawa, Jun Masuoka, Tatsuya Abe   +6 more
doaj   +1 more source

The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis

BMC Endocrine Disorders, 2021
Background Prolactinoma is the major cause of hyperprolactinemia, and dopamine agonists (DAs) are generally the first-line treatment for them. Several studies have reviewed the recurrent rate of hyperprolactinemia after DAs withdrawal.
Yunzhi Zou, Depei Li, Jiayu Gu, Siyu Chen, Xia Wen, Jiajun Dong, Xiaobing Jiang   +6 more
doaj   +1 more source

The Efficacy of Pharmacotherapy Intervention on Anthropometric Outcomes in Survivors of Childhood Brain Tumors: An Updated Systematic Review and Meta‐Analysis

Obesity Reviews, Volume 27, Issue 10, October 2026.
ABSTRACT Introduction Many survivors of childhood brain tumors face long‐term adverse health outcomes like obesity. Uncertainties surround the effect of interventions to manage obesity‐related outcomes in survivors of childhood brain tumors. The goal of this updated systematic review and meta‐analysis was to provide the best estimate of the treatment ...
David Hart, Lawrence Mbuagbaw, Joseph Beyene, Marwa Akola, Sarah Burrow, M. Constantine Samaan, Lehana Thabane, Adam Fleming, Donna L. Johnston, Shahrad R. Rassekh, Laura Banfield, Russell J. de Souza   +11 more
wiley   +1 more source

Exploring retinal vessel density alterations in prolactinoma patients: Insights from OCTA imaging

Indian Journal of Ophthalmology
Purpose: To investigate microvascular changes in the macular and peripapillary area in prolactinoma patients by using optical coherence tomography angiography (OCTA). Design: A retrospective study.
Serife Ciloglu Hayat, Yusuf Cem Yilmaz, Merve Kelebek, Esra Hatipoglu   +3 more
doaj   +1 more source